Aesthetic Efficacy of a Novel Topical Combination Brightening Regimen to Treat Facial Hyperpigmentation

Lisa T. Goberdhan, MSHS¹, Katie Schneider, BS¹, Arielle Bautista, BS¹, Elizabeth T. Makino, BS CCRA MBA¹, Rahul C. Mehta, PhD¹

¹Allergan Aesthetics, an AbbVie Company, Irvine, CA, USA

OBJECTIVE
To assess the cosmetic changes of a combination regimen of a novel brightening serum, spot treatment and brightening pads in subjects with mild to severe facial hyperpigmentation.

CONCLUSIONS
Visible improvements in the appearance of hyperpigmentation, photodamage, tactile roughness, lines/wrinkles, radiance, and skin tone evenness with consistent use of the EC Regimen

METHODS
Study Design: 12 week, Open-label, Single-Center Study

Participants
- n=19; males and females aged 31-69, self-identified ethnicities: Asian, White, American Indian, and Hispanic
- Fitz I-IV with mild to severe overall facial hyperpigmentation (score of 3-9 on a modified Griffiths 10-point scale) on the face

Study Assessments
- Dark Spot Intensity and Dark Spot Contrast grades
- Modified Melasma Area and Severity Index (mMASI) scores
- Observations of Overall Hyperpigmentation, Overall Photodamage, Tactile Roughness, Skin Tone Evenness, Fine and Coarse Lines/Wrinkles, and Radiance
- Participant self-assessment questionnaires

INTRODUCTION
- Hyperpigmentation is a multifaceted condition that is often challenging to treat.
- Due to this complexity, a combination therapy providing a holistic approach of removal and prevention of pigmentation has shown greater efficacy than a monotherapy treatment.
- A clinical usage study was conducted to assess the cosmetic changes of a combination take-home skincare topical regimen of a novel brightening platform (EC regimen: pads, serum, and spot cream) in subjects with mild to severe facial hyperpigmentation.

RESULTS
EC Regimen significantly improved dark spot (a) intensity and (b) contrast as early as Week 1 with continued improvements through Week 12 relative to baseline

Modified MASI scores following consistent use of the EC Regimen were improved as early as week 2 with continued improvements through week 12 versus baseline

Visible improvements in hyperpigmentation, photodamage, line/wrinkles, texture, and radiance of a 69-year-old, Asian female with Fitzpatrick Skin Type III at Baseline, Week 1, and Week 12 (VISIA-CR parallel-polarized images)

Tolerability scores remained mild for all tolerability parameters throughout the study

EC Regimen was a well-tolerated, effective combination for improving multiple hyperpigmentation and photoaging parameters with high patient satisfaction.